Somite.ai

Company Overview

Snapshot

Founded in October 2023 by Micha Breakstone, Olivier Pourquie, Jay Shendure, Allon Klein, Cliff Tabin, and Jonathan Rosenfeld, Somite.ai operates with 11–50 employees. The company has raised $57.5M across 3 funding rounds from 16 investors, with Khosla Ventures leading a significant Series A round in May 2025.

Business overview

Somite.ai is developing an AI-based platform to produce human tissue for cell-based therapies, aiming to revolutionize stem cell biology. Its core technology, the AlphaStem AI platform, enables the creation of new cell therapies and generates data to further improve the platform for faster therapy development. The company is targeting diseases such as diabetes, obesity, and muscular dystrophies, with a pipeline that includes programs for Duchenne muscular dystrophy (SMT-M01) and metabolic disorders (SMT-B01). Somite.ai operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering.

Strategic signal

In May 2025, Somite.ai secured a $47.5 million Series A funding round, signaling strong investor confidence in its AI platform for cell therapy development. This substantial investment, led by Khosla Ventures, validates the company's approach to leveraging AI foundation models like DeltaStem to scale the production of human cells for therapeutic applications. The funding is a critical catalyst for accelerating the company's pipeline and expanding its technological capabilities, positioning Somite.ai as a key innovator in the intersection of AI and regenerative medicine.

Company Intelligence Q&A

What was a significant recent funding event for Somite.ai?

In May 2025, Somite.ai secured a $47.5 million Series A funding round. This round was led by Khosla Ventures.

Who are the co-founders of Somite.ai?

Somite.ai was co-founded by Micha Breakstone, Olivier Pourquie, Jay Shendure, Allon Klein, Cliff Tabin, and Jonathan Rosenfeld.

What is Somite.ai's primary technological focus?

Somite.ai focuses on developing AI foundation models, such as AlphaStem and DeltaStem, to produce human tissue for cell therapies at scale. This technology aims to revolutionize stem cell biology.

What diseases is Somite.ai targeting with its cell therapies?

Somite.ai's pipeline includes programs targeting diseases such as Duchenne muscular dystrophy (SMT-M01) and metabolic disorders (SMT-B01).

When was Somite.ai founded?

Somite.ai was founded in October 2023.